NCT06599619 2026-01-26
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
University of Pittsburgh
Recruiting
Clinical Trials
10 trialsNCT07092670 2025-09-05
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Intergruppo Melanoma Italiano
Recruiting
NCT06627595 2024-11-15
APiTOXMM
University Hospital, Montpellier
Recruiting
NCT02791594 2024-11-08
Imaging FDG Flare in Melanoma
Abramson Cancer Center at Penn Medicine
Completed
NCT02600169 2024-05-06
Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab
University Medical Center Groningen
Completed
NCT05611229 2023-04-06
Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden
Novartis
Completed
NCT02909348 2023-03-02
PASIP
Royal Free Hospital NHS Foundation Trust
Completed
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT03197636 2022-03-03
Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients
Aarhus University Hospital
Completed
NCT04860076 2021-04-26
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Unknown